Enlightenment Research LLC Takes $280,000 Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

Enlightenment Research LLC acquired a new position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 614 shares of the medical research company’s stock, valued at approximately $280,000.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. Norges Bank acquired a new stake in Thermo Fisher Scientific during the 4th quarter worth $2,336,640,000. FMR LLC grew its stake in Thermo Fisher Scientific by 5.6% during the 4th quarter. FMR LLC now owns 13,022,987 shares of the medical research company’s stock valued at $6,065,847,000 after acquiring an additional 686,768 shares in the last quarter. BlackRock Inc. raised its holdings in Thermo Fisher Scientific by 2.2% in the 4th quarter. BlackRock Inc. now owns 29,504,221 shares of the medical research company’s stock valued at $13,742,475,000 after acquiring an additional 624,512 shares during the last quarter. Alecta Pensionsforsakring Omsesidigt boosted its holdings in shares of Thermo Fisher Scientific by 121.6% during the 1st quarter. Alecta Pensionsforsakring Omsesidigt now owns 1,048,000 shares of the medical research company’s stock worth $478,684,000 after purchasing an additional 575,000 shares during the last quarter. Finally, Bank Julius Baer & Co. Ltd Zurich increased its holdings in shares of Thermo Fisher Scientific by 473.7% in the fourth quarter. Bank Julius Baer & Co. Ltd Zurich now owns 641,921 shares of the medical research company’s stock valued at $298,994,000 after purchasing an additional 530,026 shares during the last quarter. 86.03% of the stock is currently owned by institutional investors and hedge funds.

A number of analysts have issued reports on TMO shares. Robert W. Baird reaffirmed a “buy” rating on shares of Thermo Fisher Scientific in a research note on Monday, May 3rd. Evercore ISI raised their price target on shares of Thermo Fisher Scientific from $525.00 to $540.00 and gave the stock an “outperform” rating in a report on Friday, April 16th. KeyCorp upgraded shares of Thermo Fisher Scientific from a “sector weight” rating to an “overweight” rating and set a $520.00 price target for the company in a research report on Thursday, March 18th. UBS Group cut their target price on Thermo Fisher Scientific from $588.00 to $560.00 and set a “buy” rating on the stock in a research report on Monday, March 29th. Finally, Barclays assumed coverage on Thermo Fisher Scientific in a report on Monday, March 8th. They issued an “overweight” rating and a $525.00 price objective on the stock. Three investment analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average target price of $534.45.

In related news, EVP Michel Lagarde sold 34,168 shares of Thermo Fisher Scientific stock in a transaction on Friday, May 7th. The shares were sold at an average price of $472.60, for a total value of $16,147,796.80. Following the transaction, the executive vice president now directly owns 52,629 shares in the company, valued at approximately $24,872,465.40. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 0.44% of the stock is owned by corporate insiders.

TMO stock opened at $464.91 on Friday. Thermo Fisher Scientific Inc. has a 12 month low of $330.57 and a 12 month high of $532.57. The company has a debt-to-equity ratio of 0.53, a quick ratio of 1.91 and a current ratio of 2.53. The stock has a market cap of $182.72 billion, a P/E ratio of 23.41, a price-to-earnings-growth ratio of 1.08 and a beta of 0.76. The firm has a fifty day simple moving average of $467.53.

Thermo Fisher Scientific (NYSE:TMO) last announced its earnings results on Thursday, April 29th. The medical research company reported $7.21 EPS for the quarter, beating analysts’ consensus estimates of $6.69 by $0.52. The business had revenue of $9.91 billion during the quarter, compared to analysts’ expectations of $9.69 billion. Thermo Fisher Scientific had a net margin of 22.08% and a return on equity of 28.95%. The business’s revenue was up 59.0% compared to the same quarter last year. During the same period in the prior year, the company earned $2.94 earnings per share. As a group, research analysts anticipate that Thermo Fisher Scientific Inc. will post 22 EPS for the current year.

The business also recently announced a quarterly dividend, which will be paid on Thursday, July 15th. Stockholders of record on Tuesday, June 15th will be issued a $0.26 dividend. This represents a $1.04 dividend on an annualized basis and a dividend yield of 0.22%. The ex-dividend date is Monday, June 14th. Thermo Fisher Scientific’s payout ratio is currently 5.32%.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Featured Article: What does earnings per share mean?

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.